TELA Bio (NASDAQ:TELA) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Posted by Brian Himes on May 12th, 2026

TELA Bio (NASDAQ:TELA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%.

Here are the key takeaways from TELA Bio’s conference call:

Management said the U.S. commercial reset is showing early proof points, with the field force now fully staffed and new hires ramping toward expected productivity inflection points in the second half of 2026.
TELA launched OviTex LTR in the U.S., a fully resorbable tissue-based hernia repair option, and said early surgeon feedback has been overwhelmingly positive. The company believes it broadens the portfolio and could help attract new surgeons.
International momentum was strong, with Europe revenue up 41% year over year, led by the U.K. and supported by validation from the NHS supply chain value-based procurement evaluation.
First-quarter revenue rose 3% to $19.1 million, while gross margin was 66% and operating loss was flat year over year at $10.5 million. The company reiterated full-year 2026 guidance for at least 8% revenue growth and Q2 revenue of about $20 million.
OviTex PRS revenue was essentially flat year over year, and management said utilization dipped because several high-volume implanters were unavailable. The company is trying to reduce this concentration risk by training more surgeons per account.

TELA Bio Stock Performance

Shares of NASDAQ TELA traded up $0.05 during midday trading on Tuesday, reaching $1.02. 318,830 shares of the stock were exchanged, compared to its average volume of 202,797. The firm has a market cap of $45.67 million, a price-to-earnings ratio of -1.23 and a beta of 1.30. TELA Bio has a twelve month low of $0.50 and a twelve month high of $2.20. The firm has a 50-day simple moving average of $0.75 and a two-hundred day simple moving average of $0.96. The company has a quick ratio of 3.59, a current ratio of 4.20 and a debt-to-equity ratio of 8.82.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Canaccord Genuity Group reduced their price objective on TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Lake Street Capital reduced their price objective on TELA Bio from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a report on Tuesday, April 21st. Citizens Jmp reduced their target price on shares of TELA Bio from $5.00 to $3.00 and set a “market outperform” rating for the company in a report on Friday, March 27th. Finally, Piper Sandler reduced their target price on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating for the company in a report on Wednesday, March 25th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $2.20.

View Our Latest Research Report on TELA

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TELA. Citadel Advisors LLC increased its holdings in TELA Bio by 161.3% in the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after buying an additional 21,781 shares in the last quarter. Susquehanna International Group LLP increased its holdings in TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after buying an additional 72,594 shares in the last quarter. Renaissance Technologies LLC increased its holdings in TELA Bio by 101.4% in the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after buying an additional 64,800 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in TELA Bio in the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 94.35% of the company’s stock.

About TELA Bio

(Get Free Report)

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.